← Back to Search
Phase II Study Of Cediranib In Patients With Malignant Pleural Mesothelioma: SWOG S0509
L. Garland, K. Chansky, A. Wozniak, A. Tsao, S. Gadgeel, C. Verschraegen, Marco A Dasilva, M. Redman, D. Gandara
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
Introduction: Malignant pleural mesothelioma (MPM) tumors express vascular epithelial growth factor (VEGF) and VEGF receptors. We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy. Methods: Patients with MPM previously treated with a platinum-containing chemotherapy regimen and a performance status 0 to 2 were eligible for enrollment. Cediranib 45 mg/d was administered until progression or unacceptable toxicity. The primary end point was response rate. Tumor measurements were made by RECIST criteria, with a subset analysis conducted using modified RECIST. A two-stage design with an early stopping rule based on response rate was used. Results: Fifty-four patients were enrolled. Of 47 evaluable patients, 4 patients (9%) had objective responses, 16 patients (34%) had stable disease, 20 patients (43%) had disease progression, 2 patients (4%) had symptomatic deterioration, and 1 patient (2%) had early death. The most common toxicities were fatigue (64%), diarrhea (64%), and hypertension (70%); 91% of patients required a dose reduction. Median overall survival was 9.5 months, 1-year survival was 36%, and median progression-free survival was 2.6 months. Conclusion: Cediranib monotherapy has modest single-agent activity in MPM after platinum-based therapy. However, some patient tumors were highly sensitive to cediranib. This study provides a rationale for further testing of cediranib plus chemotherapy in MPM and highlights the need to identify a predictive biomarker for cediranib.
This paper references
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor
N Yamamoto (2009)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
Co-Expression of Vascular Endothelial Growth Factor and Its Receptor flt-1 in Malignant Pleural Mesothelioma
J. Koenig (2000)
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
Combined Anti-Angiogenic Therapy Targeting PDGF and VEGF Receptors Lowers the Interstitial Fluid Pressure in a Murine Experimental Carcinoma
Agnieszka Kłosowska-Wardęga (2009)
Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
K. Pietras (2001)
Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)
A. Nowak (2008)
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
S. Kao (2010)
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
C. Willett (2004)
Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2006)
STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.
K. Pietras (2003)
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
F. Demirag (2005)
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
N. Yamamoto (2009)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
G. Goss (2010)
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
C. Ryan (2007)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
S. Laurie (2008)
A. DE GASPERIS (1950)
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
J. Drevs (2007)
J. Espinosa Arranz (1994)
Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model.
M. Hofmann (2009)
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307)
P. Jänne (2007)
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P. Therasse (2000)
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
Latent period for malignant mesothelioma of occupational origin.
B. Lanphear (1992)
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
U. Matulonis (2009)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
C. Heckman (2008)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
The European mesothelioma epidemic
J. Peto (1999)
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
S. Wedge (2005)
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
K. Pietras (2002)
Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy
P. Dickson (2007)
This paper is referenced by
Molecular pathogenesis of malignant mesothelioma.
P. Rascoe (2012)
Second line therapy in malignant pleural mesothelioma: A systematic review.
W. Buikhuisen (2015)
Malignant Pleural Mesothelioma: From the Bench to the Bedside
P. Astoul (2012)
INIBIDORES DAS TIROSINACINASES NA TERAPÊUTICA FARMACOLÓGICA
Sara Saraiva (2013)
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
A. Tsao (2017)
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
J. Remon (2015)
A review of bevacizumab in the treatment of malignant pleural mesothelioma.
S. Brosseau (2017)
Emerging therapies in malignant pleural mesothelioma.
M. Cinausero (2019)
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
F. Musumeci (2012)
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
New directions in mesothelioma treatment
Anna K. Nowak (2015)
Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice
G. Ceresoli (2014)
Targeting receptor tyrosine kinases in malignant pleural mesothelioma: Focus on FGF-receptors
K. Schelch (2015)
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
F. Grosso (2018)
alignant pleural mesothelioma
F. Honeyball (2013)
The role of cediranib in ovarian cancer: current status and further investigation
J. Ethier (2016)
Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
D. Signorelli (2016)
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
I. Judson (2014)
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
N. Campbell (2012)
The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma
E. Pulford (2017)
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment
C. V. van Herpen (2013)
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma.
M. Disselhorst (2020)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
Mesothelioma: is chemotherapy alone a thing of the past?
A. Bibby (2020)
Molecular pathogenesis of malignant mesothelioma.
Y. Sekido (2013)
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Fabio Nicolini (2019)
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma
E. McWhirter (2016)
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma
Emyr Bakker (2017)See more